| Not Yet Recruiting | A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events NCT07474649 | Daiichi Sankyo | Phase 3 |
| Active Not Recruiting | A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hyper NCT07206472 | Daiichi Sankyo | — |
| Not Yet Recruiting | ATLANTIS Trial: Phospholipid Omega-3 Versus Conventional Omega-3 NCT07394517 | Fundación del Caribe para la Investigación Biomédica | N/A |
| Enrolling By Invitation | A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of AD-117 in NCT07495514 | Addpharma Inc. | Phase 1 |
| Not Yet Recruiting | A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A NCT07152873 | Addpharma Inc. | Phase 1 |
| Completed | Clinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect NCT07319559 | Daewon Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | The Food Effect on PK Characteristics and Safety Profiles of PA-111 NCT06976489 | Addpharma Inc. | Phase 1 |
| Completed | Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monot NCT07444762 | Daewon Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A NCT06932705 | Addpharma Inc. | Phase 1 |
| Recruiting | A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients Wi NCT06686615 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | — |
| Completed | A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Ad NCT07409636 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary NCT06386419 | Novartis Pharmaceuticals | Phase 4 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib NCT06314919 | Boryung Pharmaceutical Co., Ltd | — |
| Active Not Recruiting | A Study in Patients With Mixed Dyslipidemia NCT06497127 | Shanghai Argo Biopharmaceutical Co., Ltd. | Phase 2 |
| Withdrawn | Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in NCT05798390 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | — |
| Active Not Recruiting | Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD NCT05399992 | Novartis Pharmaceuticals | — |
| Recruiting | A Study to Evaluate the Efficacy and Safety of AD-218 NCT05400317 | Addpharma Inc. | Phase 3 |
| Completed | SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to NCT05546398 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | — |
| Completed | Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholest NCT05118230 | Novartis Pharmaceuticals | — |
| Completed | Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia NCT04998201 | Arrowhead Pharmaceuticals | Phase 2 |
| Completed | Study of ARO-ANG3 in Adults With Mixed Dyslipidemia NCT04832971 | Arrowhead Pharmaceuticals | Phase 2 |
| Unknown | An Observational Study on the Identification of Prescription Patterns of STAFEN Cap NCT06204380 | Hanlim Pharm. Co., Ltd. | — |
| Active Not Recruiting | Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia NCT04579367 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | — |
| Terminated | Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participa NCT03433755 | Amgen | Phase 3 |
| Unknown | A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe NCT03648788 | IlDong Pharmaceutical Co Ltd | — |
| Completed | Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia NCT02739984 | Amgen | Phase 3 |
| Completed | Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on t NCT02275156 | Amgen | Phase 1 |
| Completed | Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a P NCT01879319 | Amgen | Phase 3 |
| Completed | Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen NCT01849497 | Amgen | Phase 3 |
| Completed | Bezafibrate Plus Berberine in Mixed Dyslipidemia NCT02548832 | University of Guadalajara | Phase 3 |
| Terminated | Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hyperchol NCT01335997 | Merck Sharp & Dohme LLC | Phase 3 |
| Terminated | Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy NCT01274559 | Merck Sharp & Dohme LLC | Phase 3 |
| Terminated | Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119) NCT01228019 | Merck Sharp & Dohme LLC | — |
| Completed | Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixe NCT01256476 | Kowa Research Institute, Inc. | Phase 4 |
| Completed | Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coa NCT00639158 | Abbott | Phase 3 |
| Completed | Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) NCT00479388 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | MK-0524B Lipid Study (MK-0524B-063) NCT00479882 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dysl NCT00491530 | Abbott | Phase 3 |
| Completed | An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects NCT00465088 | Abbott | Phase 3 |
| Completed | An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipide NCT00487591 | Provident Clinical Research | — |
| Completed | Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in NCT00300430 | Abbott | Phase 3 |
| Completed | Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abn NCT00300482 | Abbott | Phase 3 |
| Completed | Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Li NCT00300469 | Abbott | Phase 3 |
| Completed | Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lip NCT00300456 | Abbott | Phase 3 |
| Completed | Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholes NCT00136799 | Novartis | Phase 3 |
| Completed | Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study NCT00309712 | Intermountain Health Care, Inc. | N/A |
| Completed | Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia NCT00171236 | Novartis | Phase 3 |